SNBTS Cell Therapy Group, MRC Centre for Regenerative Medicine, The University of Edinburgh, Edinburgh, UK.
J Thromb Haemost. 2010 Jul;8(7):1614-23. doi: 10.1111/j.1538-7836.2010.03900.x. Epub 2010 May 4.
The most common source of hematopoietic progenitor cells (HPCs) for hematopoietic reconstitution comprises granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood stem cells (PBSCs). It has been proposed that endothelial progenitor cells (EPCs) share precursors with HPCs, and that EPC release may accompany HPC mobilization to the circulation following G-CSF administration.
To investigate EPC activity following HPC mobilization, and the direct effects of exogenous G-CSF administration on human umbilical vein endothelial cells (HUVECs) and endothelial outgrowth cells (EOCs), using in vitro and in vivo correlates of angiogenesis.
PATIENTS/METHODS: Heparinized venous blood samples were collected from healthy volunteers and from cord blood at parturition. G-CSF-mobilized samples were collected before administration, at apheresis harvest, and at follow-up. PBSCs were phenotyped by flow cytometry, and cultured in standard colony-forming unit (CFU)-EPC and EOC assays. The effect of exogenous G-CSF was investigated by addition of it to HUVECs and EOCs in standard tubule formation and aortic ring assays, and in an in vivo sponge implantation model.
Our data show that G-CSF mobilization of PBSCs produces a profound, reversible depression of circulating CFU-EPCs. Furthermore, G-CSF administration did not mobilize CD34+CD133- cells, which include precursors of EOCs. No EOCs were cultured from any mobilized PBSCs studied. Exogenous G-CSF inhibited CFU-EPC generation, HUVEC and EOC tubule formation, microvessel outgrowth, and implanted sponge vascularization in mice.
G-CSF administration depresses both endothelial cell angiogenesis and monocyte proangiogenic activity, and we suggest that any angiogenic benefit observed following implantation of cells mobilized by G-CSF may come only from a paracrine effect from HPCs.
造血祖细胞(HPC)最常见的来源是粒细胞集落刺激因子(G-CSF)动员的外周血干细胞(PBSC)。有人提出内皮祖细胞(EPC)与 HPC 共享前体细胞,并且在 G-CSF 给药后 EPC 释放可能伴随着 HPC 动员到循环中。
通过体外和体内血管生成相关物来研究 HPC 动员后 EPC 活性,以及外源性 G-CSF 给药对人脐静脉内皮细胞(HUVEC)和内皮细胞外生(EOC)的直接影响。
患者/方法:从健康志愿者和分娩时的脐带血中采集肝素化静脉血样本。在给药前、采集时和随访时采集 G-CSF 动员的样本。通过流式细胞术对 PBSC 进行表型分析,并在标准集落形成单位(CFU)-EPC 和 EOC 测定中进行培养。通过将其添加到 HUVEC 和 EOC 中进行标准管形成和主动脉环测定,以及在体内海绵植入模型中,研究外源性 G-CSF 的作用。
我们的数据表明,G-CSF 动员 PBSC 会导致循环 CFU-EPC 发生深刻且可逆的抑制。此外,G-CSF 给药不会动员包括 EOC 前体的 CD34+CD133-细胞。从任何动员的 PBSC 中均未培养出 EOC。外源性 G-CSF 抑制 CFU-EPC 的生成、HUVEC 和 EOC 的管形成、微血管生长和植入小鼠海绵的血管化。
G-CSF 给药可抑制内皮细胞血管生成和单核细胞促血管生成活性,我们认为,通过 G-CSF 动员植入细胞观察到的任何血管生成益处可能仅来自 HPC 的旁分泌作用。